British Journal of Cancer - McMaster Experts

publication venue for

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas 2006
Randomised trial testing intensity modulated radiotherapy and partial organ radiotherapy in early breast cancer (import trial) 2004
Hypoxia inducible factor (HIF)-1 alpha in non-small cell lung cancer (NSCLC) 2002
beta-catenin in non-small cell lung cancer (NSCLC) 2002
Adjuvant taxanes for early breast cancer - Clinical uncertainty exists 2001
The Wnt-APC-beta catenin pathway in phyllodes tumours 2001
Effects of low level radiation in normal urothelial cells 1999
Prognostic significance of platelet microvessel counts in non-small cell lung cancer 1999
Apoptotic index as a prognostic factor in a trial of primary medical therapy for carcinoma of the breast. 1998
CHANGES IN PROTEIN EXPRESSION DURING MELANOMA DIFFERENTIATION DETERMINED BY COMPUTER-ANALYSIS OF 2-D GELS 1990
CISPLATIN INVOKED LEAD MOBILIZATION STUDIES 1990
DEVELOPMENT OF A TECHNIQUE FOR OPTIMIZING CANCER-THERAPY USING A HUMAN EPITHELIAL MODEL SYSTEM 1988
LETHAL MUTATIONS AND THEIR EFFECT ON THE APPLICATION OF RADIOBIOLOGICAL RESULTS TO RADIOTHERAPY 1988
ENDOCRINE DISORDERS FOLLOWING TREATMENT OF BRAIN-TUMORS IN CHILDHOOD 1987
GROWTH FAILURE FOLLOWING IRRADIATION IN CHILDREN WITH BRAIN-TUMORS 1987
A HISTOPATHOLOGICAL AND DNA CYTOPHOTOMETRIC STUDY OF BENIGN AND MALIGNANT ESOPHAGEAL TISSUE CULTURED INVITRO 1987
A MODEL FOR THE STUDY OF TREATMENT RESPONSE IN HUMAN NORMAL AND TUMOR-CELLS INVITRO 1987
HIGH-DOSE BCNU PRIMARY CHEMOTHERAPY WITH FULL DOSE RADIOTHERAPY FOR ASTROCYTOMA GRADE-IV 1987
ANALYSIS OF THE HUMAN ANTI-MOUSE IG RESPONSE IN PATIENTS RECEIVING MURINE MONOCLONAL-ANTIBODIES 1986
LACK OF CORRELATION BETWEEN EXCISION REPAIR OF UV DAMAGE AND ADENOVIRUS REACTIVATION IN AN XP(D)-LIKE CELL-LINE 1986
RADIATION RESPONSE OF HUMAN ESOPHAGEAL CELLS-INVITRO 1986
HUMAN ANTI-MOUSE IMMUNOGLOBULIN RESPONSES IN PATIENTS RECEIVING MONOCLONAL-ANTIBODIES 1985
THE EFFECT OF ALTERED ENERGY-METABOLISM ON THE PRIMARY AND SECONDARY SURVIVAL-CURVE SHOULDER OF IRRADIATED CHO-KI CELLS 1984
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. 130:269-274. 2024
Correction: Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada. 129:1362-1362. 2023
Maternal and childhood medical history and the risk of childhood brain tumours: a case–control study in Ontario, Canada. 129:318-324. 2023
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. 128:2283-2294. 2023
Timeliness of diagnosis and treatment: the challenge of childhood cancers. 125:1612-1620. 2021
Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers. 125:1178-1178. 2021
Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. 124:1503-1512. 2021
The association between colorectal cancer and prior antibiotic prescriptions: case control study. 122:912-917. 2020
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. 121:15-21. 2019
Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. 119:707-712. 2018
Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). 118:1434-1441. 2018
Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. 118:1238-1242. 2018
The effect of selection and referral biases for the treatment of localised prostate cancer with surgery or radiation. 118:1399-1405. 2018
A machine learning approach to radiogenomics of breast cancer: a study of 922 subjects and 529 DCE-MRI features. 119:508-516. 2018
Evaluation of treatment-related mortality among paediatric cancer deaths: a population based analysis. 116:540-545. 2017
Impact of cause of death adjudication on the results of the European prostate cancer screening trial. 116:141-148. 2017
The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. 114:1160-1164. 2016
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. 114:616-622. 2016
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial. 113:722-728. 2015
18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. 112:1737-1743. 2015
A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177. 111:2262-2267. 2014
Refinement of the Symptom Screening in Pediatrics Tool (SSPedi). 111:1262-1268. 2014
Aldehyde dehydrogenase 3A1 associates with prostate tumorigenesis. 110:2593-2603. 2014
Validation of the Children’s International Mucositis Evaluation Scale (ChIMES) in paediatric cancer and SCT. 109:2515-2522. 2013
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503). 109:943-949. 2013
Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. 108:2021-2032. 2013
Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. 108:327-333. 2013
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials. 106:1626-1637. 2012
Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. 105:1469-1473. 2011
Postmenopausal circulating levels of 2- and 16α-hydroxyestrone and risk of endometrial cancer. 105:1458-1464. 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. 105:1144-1150. 2011
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. 105:884-889. 2011
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. 105:709-722. 2011
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. 105:44-52. 2011
Statistical issues in the use of dynamic allocation methods for balancing baseline covariates. 104:1711-1715. 2011
Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. 104:1377-1383. 2011
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. 104:756-762. 2011
Family history and the risk of gastric cancer. 102:237-242. 2010
Incidence and predictors of treatment-related mortality in paediatric acute leukaemia in El Salvador. 100:1026-1031. 2009
A prospective study of peri-diagnostic and surgical wait times for patients with presumptive colorectal, lung, or prostate cancer. 100:56-62. 2009
Identification of paediatric cancer patients with poor quality of life. 100:82-88. 2009
Rapid progression of prostate cancer in men with a BRCA2 mutation. 99:371-374. 2008
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. 97:302-307. 2007
Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. 96:1526-1531. 2007
Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. 94:1452-1459. 2006
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. 94:1136-1143. 2006
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. 94:1011-1015. 2006
Singlet oxygen luminescence as an in vivo photodynamic therapy dose metric: validation in normal mouse skin with topical amino-levulinic acid. 92:298-304. 2005
Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. 91:1301-1307. 2004
Relationship between clonogenic radiosensitivity, radiation-induced apoptosis and DNA damage/repair in human colon cancer cells. 89:2277-2283. 2003
Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. 89:1979-1986. 2003
Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. 89:954-954. 2003
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. 89:1031-1034. 2003
Oestradiol enhances tumour regression induced by B7-1/IL-2 adenoviral gene transfer in a murine model of breast cancer. 89:385-390. 2003
A proliferation-dependent bystander effect in primary porcine and human urothelial explants in response to targeted irradiation. 88:767-774. 2003
Particulate debris from a titanium metal prosthesis induces genomic instability in primary human fibroblast cells. 88:548-552. 2003
Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans. 86:1751-1756. 2002
First do no harm: extending the debate on the provision of preventive tamoxifen. 85:1280-1288. 2001
Production of a signal by irradiated cells which leads to a response in unirradiated cells characteristic of initiation of apoptosis. 83:1223-1230. 2000
True. 82:1740-1746. 2000
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. 82:1427-1432. 2000
Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. 82:361-367. 2000
Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. 81:490-495. 1999
Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. 80:815-820. 1999
Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. 79:1428-1436. 1999
Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. 77:1429-1438. 1998
A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. 75:1014-1020. 1997
Erratum: The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. 74:1691-1691. 1996
p53 protein is absent from the serum of patients with lung cancer. 74:1434-1440. 1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. 74:1242-1247. 1996
A randomised trial of two information packages distributed to new cancer patients before their initial appointment at a regional cancer centre. 73:1588-1593. 1996
Nasopharyngeal carcinoma: an EBV-associated tumour not significantly influenced by HIV-induced immunosuppression. 73:995-997. 1996
The sensitivity of normal brain and intracranially implanted VX2 tumour to interstitial photodynamic therapy. 73:332-343. 1996
What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. 73:222-227. 1996
Diagnostic and therapeutic approaches to lung cancer in Canada and their costs. 72:1270-1277. 1995
Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. 72:720-727. 1995
Prostate-specific antigen in serum of women with breast cancer. 72:728-731. 1995
Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. 71:25-29. 1995
The comprehensive assessment of health status in survivors of childhood cancer: application to high-risk acute lymphoblastic leukaemia. 67:1047-1052. 1993
The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. 65:737-743. 1992
The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. 65:130-132. 1992
Endocrine disorders following treatment of childhood brain tumours. 61:622-625. 1990
Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy?. 59:910-914. 1989
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. 58:779-782. 1988
Cross resistance pattern towards anticancer drugs of a human carcinoma multidrug-resistant cell line. 58:441-447. 1988
Human ovarian carcinoma: evidence for patient-related differences in susceptibility to cytotoxic effectors that attack different cellular subpopulations within a tumour. 58:415-418. 1988
VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. 58:464-468. 1988
Double antibody radioimmunoassay for monitoring metastatic breast cancer. 58:362-367. 1988
A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. 57:94-99. 1988
Cellular heterogeneity in normal and neoplastic human urothelium: A study using murine monoclonal antibodies. 56:439-444. 1987
Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. 55:541-542. 1987
RADIATION TRANSFORMATION IN DIFFERENTIATED HUMAN-CELLS IN CULTURE. 53:251-252. 1986
Evaluation of screening programmes for gynaecological cancer. 52:669-673. 1985
Soft-tissue injury caused by antineoplastic drugs is inhibited by topical dimethyl sulphoxide and alpha tocopherol. 48:873-876. 1983
Soft-tissue necrosis induced by extravasated cancer chemotherapeutic agents: A study of active intervention. 44:267-269. 1981
FURTHER CLINICAL EXPERIENCES OF A PHASE-I STUDY WITH HYPOXIC CELL RADIOSENSITIZER MISONIDAZOLE. 37:281-285. 1978

British Journal of Cancer Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)